Ann: Noxopharm March 2020 Quarterly Report & Appendix 4C, page-3

  1. 1,021 Posts.
    lightbulb Created with Sketch. 334
    I suppose the pending announcement on the FDA approval for trialling Veyonda against Covid-19 will be used as a catalyst to bolster the SP in the coming weeks.

    From a TA point of view I see this possibly having a nudge between 29c to 35c and may get there with that news within the specified 4 weeks. My mobile chart is a little crude but you can see an inverse H&S pattern there.

    https://hotcopper.com.au/data/attachments/2128/2128270-d3cf871b227a6fe0eaf9c4b0a2a56e77.jpg


 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
6.8¢
Change
0.005(7.94%)
Mkt cap ! $19.87M
Open High Low Value Volume
6.5¢ 6.9¢ 6.5¢ $48.42K 724.1K

Buyers (Bids)

No. Vol. Price($)
1 30000 6.7¢
 

Sellers (Offers)

Price($) Vol. No.
6.8¢ 2284 1
View Market Depth
Last trade - 16.10pm 18/07/2025 (20 minute delay) ?
NOX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.